Precigen

@Precigen

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies.

Vrijeme pridruživanja: siječanj 2018.

Tweetovi

Blokirali ste korisnika/cu @Precigen

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Precigen

  1. Prikvačeni tweet
    3. velj

    Congratulations to the team and our new shareholders for the start of a new chapter. We look forward to continuing to live by our brand promise to advance medicine with precision.

    Poništi
  2. 4. velj

    Today is . Join as we strive to find new therapies for difficult-to-treat cancers. Together, we can advance medicine with precision in the pursuit of new treatment options.

    Poništi
  3. 3. velj

    Welcome investors to . This new site provides the latest updates on and our progress as we advance medicine with precision.

    Poništi
  4. 3. velj
    Poništi
  5. 29. sij

    Thank you for hosting the Annual Annapolis Day & Leadership Dinner. enjoyed speaking with General Assembly Members about delivering innovative solutions to pressing healthcare challenges.

    Poništi
  6. 15. sij

    - Precigen provides 2020 preclinical milestones during - an exciting year ahead for the company!

    Poništi
  7. 15. sij

    - Precigen provides 2020 clinical milestones during

    Poništi
  8. 15. sij

    - Check out Precigen's latest clinical and partnered pipeline presented at

    Poništi
  9. 15. sij

    - Check out Precigen's preclinical pipeline presented at

    Poništi
  10. 13. sij

    Join Dr. Helen Sabzevari, President and CEO of Precigen, at for her presentation on Precigen’s progress and a 2020 look ahead.

    Poništi
  11. proslijedio/la je Tweet
    7. sij

    Just four days after Germantown's Intrexon Corp. made public plans to rebrand as Precigen, its subsidiary by the same name has secured a coveted regulatory designation for its blood cancer treatment.

    Poništi
  12. 6. sij

    receives first regulatory designation for PRGN-3006 UltraCAR-T

    Poništi
  13. 2. sij

    appoints Helen Sabzevari, PhD, as new President and CEO and will change name to to reflect healthcare focus. Join us at on January 14 at 5pm PT to hear Helen's vision for the new Precigen

    Poništi
  14. 23. pro 2019.

    Team celebrates the holidays in our offices! from our family to yours

    Poništi
  15. 11. pro 2019.

    Thank you for hosting this morning’s Legislative Policy Breakfast in . enjoyed discussing and Initiatives with General Assembly Members

    Poništi
  16. 2. pro 2019.

    Dr. Helen Sabzevari, President of , will speak at the upcoming World Vaccine & Immunotherapy Congress in San Francisco. Join us! -T

    Poništi
  17. 27. stu 2019.
    Poništi
  18. 22. stu 2019.
    Poništi
  19. 22. stu 2019.

    team, including President Dr. Helen Sabzevari and County Executive and his team discuss mechanisms to support and in

    Poništi
  20. 19. stu 2019.

    ’s Tim Chan to present preclinical data from PRGN-3006 UltraCAR-T at in Orlando, FL

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·